Active, not recruitingPhase 2NCT04802161

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Studying Acute myeloid leukaemia with myelodysplasia-related features

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Joshua F Zeidner, M.D
Ohio State University Comprehensive Cancer Center LAO
Intervention
Biospecimen Collection(procedure)
Enrollment
50 enrolled
Eligibility
18-75 years · All sexes
Timeline
20222026

Study locations (11)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04802161 on ClinicalTrials.gov

Other trials for Acute myeloid leukaemia with myelodysplasia-related features

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukaemia with myelodysplasia-related features

← Back to all trials